We currently manufacture 200 Regular TCMP products listed on China Pharmacopoeia (version 2020) Parts I and IV for hospitals and drug stores in treatment of various diseases or serving as dietary sup…
We currently manufacture 200 Regular TCMP products listed on China Pharmacopoeia (version 2020) Parts I and IV for hospitals and drug stores in treatment of various diseases or serving as dietary sup…
NOTE 10 – BORROWINGS (CONTINUED) Long-term borrowings (Continued) Long-term bank loans are loans the Company borrowed from Jiangsu Taizhou Rural Commercial Bank which are valid from November 2, 2022 …
China SXT Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SXTC-DEBT
Debt stack $1.2M
90%
Market cache reports total debt of $1.2M.
SXTC-DEBT-12847
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-03-31.
SXTC-DEBT-12846
Warrants outstanding: 0.01
90%
xbrl warrant detail from xbrl 2023-09-30.
China SXT Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for China SXT Pharmaceuticals, Inc..
China SXT Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
SXTC-OWNER-CITADEL-ADVISORS-LLC
CITADEL ADVISORS LLC
90%
13F overlay lists CITADEL ADVISORS LLC as top holder; 8 tracked holders.
China SXT Pharmaceuticals, Inc. Extended Supply Chain Network